• GelMA/QCS/Ca2+ Adhesive for Noncompressible Hemorrhage

  2026-09-07

  The reference study develops an injectable GelMA/QCS/Ca2+ double-network adhesive that combines blue-light-triggered sealing with antibacterial activity for non-compressible bleeding. In mouse injury models, the material outperformed fibrin glue and single-function hydrogels, although further work is needed to establish performance across clinically relevant wound environments.

• Dual-Action Control of p38α Dephosphorylation

  2026-09-07

  The reference preprint shows that selected kinase inhibitors can do more than block p38α catalysis: they can also expose its activation-loop phospho-threonine to the WIP1 phosphatase. This conformational mechanism suggests a route toward kinase inhibitors with phosphatase-assisted potency and specificity, while providing a framework for interpreting p38 MAPK experiments in disease-relevant models.

• Mutant Branching Enzyme Improves Pea Starch Function

  2026-09-05

  This 2026 study used structure-guided mutagenesis to improve a 1,4-α-glucan branching enzyme from Bifidobacterium longum for pea-starch modification. The S321D variant produced shorter branches, reduced retrogradation, and increased the slowly digestible starch fraction in both starch and pea cake, suggesting a useful enzyme-design strategy for texture and digestion control.

• Naftifine HCl: Assay Workflows and Use Cases

  2026-09-04

  Naftifine HCl supports mechanism-led antifungal experiments by connecting fungal growth phenotypes with squalene 2,3-epoxidase inhibition and sterol-biosynthesis readouts. This guide provides solvent-aware preparation, dose-response design, assay controls, troubleshooting, and a carefully bounded connection to WNT5a/GSK3/β-catenin research.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-09-04

  A 2025 GeroScience study developed a drug-sensitized Saccharomyces cerevisiae platform that markedly improves detection of TOR pathway inhibitors. The system distinguished known inhibitors, revealed TOR1-dependent activity for aminophylline and AZD8055, and found no detectable TOR inhibition for canagliflozin under the tested yeast conditions.

• Arsenic Neurotoxicity, BBB Disruption, and MMP-2/MMP-9

  2026-09-03

  The reference study links sodium arsenite-induced cognitive impairment in male mice to MMP-2/MMP-9-associated blood-brain barrier disruption, tight-junction loss, and hippocampal neuronal apoptosis. Its doxycycline hyclate intervention provides pharmacological evidence that suppressing these matrix metalloproteinase-associated changes can preserve BBB integrity and improve learning and memory outcomes.

• WP1066: JAK2/STAT3 Inhibitor Workflows

  2026-09-03

  WP1066 is a cell-permeable JAK2/STAT3 inhibitor for connecting phosphorylation changes with cancer-cell phenotypes, including renal carcinoma and AML models. Its value also extends to carefully controlled macrophage and biomaterial studies, where pathway inhibition can test whether JAK2-STAT3 activation is required for regenerative signaling.

• iMSC Exosomes Reprogram Macrophages in IDD

  2026-09-02

  This study identifies a reciprocal senescence–inflammation circuit between nucleus pulposus cells and macrophages in intervertebral disc degeneration. It further shows that exosomes from human induced pluripotent stem cell-derived mesenchymal stromal cells deliver miR-100-5p, suppress mTORC1-linked glycolytic reprogramming, and shift macrophages toward a less inflammatory state.

• ARCA EGFP mRNA for Transfection Workflows

  2026-09-02

  Use ARCA EGFP mRNA as a fast, directly visible control for comparing delivery reagents, lipid nanoparticles, and mammalian cell expression conditions. Its capped, polyadenylated design turns transfection optimization into a practical fluorescence-based assay rather than an indirect molecular readout.

• Metronidazole: OAT3 Assays and Research Workflows

  2026-09-01

  Metronidazole supports two complementary research directions: controlled inhibition of OAT3-mediated uptake and experimental studies of anaerobic bacteria and protozoa. This workflow guide shows how to separate transporter effects from antimicrobial activity, improve concentration-response assays, and troubleshoot common sources of variability.

• ML365 and Postoperative Cognitive Impairment

  2026-09-01

  A 2024 Brain Research study reports that ML365 pretreatment reduced postoperative cognitive impairment in aged mice while suppressing hippocampal NLRP3 inflammasome markers, oxidative stress, and tissue injury. The work connects K2P channel pharmacology with postoperative neuroinflammation, but further experiments are needed to establish direct TASK1 engagement and cell-specific mechanisms.

• Gingerenone A Restores Sunitinib Response in RCC

  2026-08-31

  A January 2026 study identifies gingerenone A as a metabolic intervention that inhibits LDHA-driven glycolysis and improves sunitinib activity in renal cell carcinoma models. Its combination of computational target discovery, metabolic assays, lactate rescue, drug-combination analysis, and in vivo validation supports glycolysis as a tractable mechanism of sunitinib resistance, while leaving clinical translation and target selectivity to be established.

• 2'3'-cGAMP: Beyond Canonical STING Assays

  2026-08-31

  2'3'-cGAMP (sodium salt) is more than a potent STING agonist: it can separate canonical type I interferon induction from emerging, STING-independent signaling. This guide translates recent interactome findings into practical assay-design decisions for innate immunity, migration, and immunotherapy research.

• N-MYC/eIF4G1 in inv(16) AML: Study Insights

  2026-08-30

  Peramangalam et al. identify a previously unrecognized MYCN enhancer and show that N-MYC sustains inv(16) acute myeloid leukemia through the translation-initiation factor eIF4G1. The study connects CBFβ-SMMHC–associated transcriptional disruption to a downstream survival dependency, offering a mechanistic framework for biomarker-guided acute myeloid leukemia research.

• VX-661 and the Next Era of CFTR Rescue

  2026-08-29

  VX-661 is more than a F508del CFTR corrector: it is a mechanistic probe for studying how protein folding, calnexin-dependent proteostasis, trafficking, and channel function converge in cystic fibrosis research.

8505 records 1/567 page Next 12345 下5页 Last page